Compare TROO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROO | MYGN |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.1M | 547.2M |
| IPO Year | N/A | 1995 |
| Metric | TROO | MYGN |
|---|---|---|
| Price | $3.96 | $5.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 584.6K | ★ 952.6K |
| Earning Date | 10-17-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,084,000.00 | ★ $825,300,000.00 |
| Revenue This Year | N/A | $0.05 |
| Revenue Next Year | N/A | $5.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 247.24 | 0.21 |
| 52 Week Low | $0.49 | $3.76 |
| 52 Week High | $5.28 | $15.47 |
| Indicator | TROO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 26.71 |
| Support Level | $3.57 | $5.03 |
| Resistance Level | $4.45 | $5.70 |
| Average True Range (ATR) | 0.36 | 0.26 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 49.32 | 4.00 |
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.